IBT 9302 (Heparinase III): a novel enzyme for the management of reperfusion injury-related vascular damage, restenosis and wound healing

Bibliography

• CASTELLOT JJ, CHOAY J, LORMEAU J-C et al.: Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells, II: Evi-dence for a pentasaccharide sequence that contains a 3-0-sulfate group. J. Cell Biol. (1986) 102:1979–1984.
   PubMed Web of Science ®Google Scholar
• LEY K, CERRITO M, ARFORS K-E: Sulfated polysaccha-rides inhibit leukocyte rolling in rabbit mesentery ye-nules. Am. J. Physiol. (1991) 260:H1667–H1673.
   PubMed Web of Science ®Google Scholar
• SCHMIDT A, YOSHIDA K, BUDDECKE E: The antiprolif-erative activity of arterial heparan sulfate resides in domains enriched with 2-0-sulfated uronic acid resi-dues. J. Biol. Chem. (1992) 267:19242–19247.
   PubMed Web of Science ®Google Scholar
• MACCARRANA M, CASU B, LINDAHL U: Minimal se-quence in heparin/heparan sulfate required for bind-ing of basic fibroblast growth factor. J. Biol. Chem. (1993) 268:23898–23905.
   PubMed Web of Science ®Google Scholar
• NELSON RM, CECCONI 0, ROBERTS W eta!: Heparin oli-gosaccharides bind L-and P-selectin and inhibit acute inflammation. Blood (1993) 82:3253–3258.
   PubMed Web of Science ®Google Scholar
• NORGARD-SUMNICHT K, VARKI NM, VARKI A: Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. Science (1993) 261:480–483.
   PubMed Web of Science ®Google Scholar
• BENEZRA M, BEN-SASSON SA, REGAN J et al Antiprolif- erative activity to vascular smooth muscle cells and re-ceptor binding of heparin-mimicking polyaromatic anionic compounds. Arterioscler. Thrum. (1994) 14:1992–1999.
   Web of Science ®Google Scholar
• JACKSON T, ELLARD FM, GHAZALEH RA et al: Efficient infection of cells in culture by type 0 foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J. Virol. (1996) 70:5282–5287.
   PubMed Web of Science ®Google Scholar
• CHEN Y, MAGUIRE T, HILEMAN RE et al. Dengue virus in- fectivity depends on envelope protein binding to tar-get cell heparan sulfate. Nature Med. (1997) 3 866–871
   PubMed Web of Science ®Google Scholar
• FEYZI E, TRYBALA E, BERGSTROM T et al.: Structural re-quirement of heparan sulfate for interaction with her-pes simplex virus type 1 virons and isolated glycoprotein C. J. Biol. Chem. (1997) 272:24850–24857.
   PubMed Web of Science ®Google Scholar
• FRYER A, HUANG Y-C, RAO G et al.: Selective 0-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J. Pharma-col. Exp. Ther. (1997) 282:208–219.
   PubMed Web of Science ®Google Scholar
• ERNST S, LANGER R, COONEY CL, SASISEKHARAN R: En-zymatic degradation of glycosaminoglycans. Crit. Rev. Biochem. Mol. Biol. (1995) 30:387–444.
   PubMed Web of Science ®Google Scholar
• SU H, BLAIN F, MUSIL RA et al: Isolation and expressionin Escherichia coli of hepB and hepC, genes encoding for the glycosaminoglycan-degrading enzymes heparinase II and heparinase III, respectively, from Flavobacterium heparinum. Appl. Environ. Microbiol. (1996) 62:2723–2734.
   PubMed Web of Science ®Google Scholar
• GOD VARTI R, DAVIS M, VENKAIRAMAN G et al: Hepari-nase III from Flavobacterium heparinum: cloning and recombinant expression in Escherichia coli. Biochem. Biophys. Res. Comm. (1996) 225:751–759.
   PubMed Web of Science ®Google Scholar
• YANG VC, LINHARDT RJ, BEASTEIN H, COONEY CL, LAN-GER R: Purification and characterization of heparinase from Flavobacterium heparium. J. Biol. Chem. (1985) 260:1849–1857.
   PubMed Web of Science ®Google Scholar
• LAWRENCE MB, SPRINGER TA: Leukocytes roll on a se-lectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell (1991) 65:859–873.
   PubMed Web of Science ®Google Scholar
• LEFER AM, LEFER DJ: Pharmacology of the endotheliumin ischemia-reperfusion and circulatory shock. Annu. Rev. Pharmacol. Toxicol. (1993) 33:71–90.
   PubMed Web of Science ®Google Scholar
• FURIE MB, RANDOLPH GJ: Chemokines and tissue in-jury. Am. J. Pathol. (1995) 146:1287–1301.
   PubMed Web of Science ®Google Scholar
• BENNETT DC, GROUIX B, CAUCHON E: Heparinase treatment decreases neutrophil-specific interactions with inflamed endothelial cells in vitro. FASEB J (1997) 11:A116. (Abstract).
   Google Scholar
• POTTER RF, CARSO MW, HARRIS KA, SCHLAG MG: Heparinase III (IBT 9302) attenuates the inflammatory response after ischaemia/reperfusion in muscle. FASEB J Abstract. (In press.)
   Google Scholar
• HAYWARD R, SCALIA R, HOPPER B et al.: Cellular mecha-nisms of heparinase III protection in rat traumatic shock. Am. J. Physiol. (In Press.).
   Google Scholar
• KINGMA JG, Jr., GROUIX B, BOUDRIAU S, BENNETT DC: Effect of heparinase III on reperfusion injury in rab-bits. FASEB J (1997) 11:A337. Abstract.
   Google Scholar
• HAYWARD R, NOSSULI TO, LEFER AM: Heparinase III ex-erts endothelial and cardioprotective effects in feline myocardial ischemia-reperfusion injury. J. Pharmacol Exp. Ther. (1997) 283:1032–1038.
   PubMed Web of Science ®Google Scholar
• KOURETAS PC, MYERS AK, KIM YO et al.: Heparin and nonanticoagulant heparin preserve regional myocar-dial contractility after ischemia-reperfusion injury: role of nitric oxide. J. Thoracic Cardiovasc. Surg. (1998) 115:440–448.
   PubMed Web of Science ®Google Scholar
• ROSS R: Platelet-derived growth factor. Ann. Rev. Med. (1987) 38:71–79.
   PubMed Web of Science ®Google Scholar
• FAGIN JA, FORRESTER JS: Growth factors, cytokines and vascular injury. Trends Cardiovasc. Med. (1992) 2:90–94.
   PubMed Web of Science ®Google Scholar
• YAYON A, KLAGSBRUN M, ESKO JD, LEDER P, ORNITZ DM: Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell (1991) 64:841–848.
   PubMed Web of Science ®Google Scholar
• GOREN H, SOKER S, VLODAVSKY I, NEUFEL G: The bind-ing of vascular endothelial growth factor to its recep-tors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. (1992) 267:6093–6098.
   PubMed Web of Science ®Google Scholar
• HIGASHIYAMA S, ABRAHAM JA, KLAGSBRUN M: Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interac-tions with cell surface heparan sulfate. J. Cell. Biol. (1993) 122:933–940.
   PubMed Web of Science ®Google Scholar
• KHACHIGIAN LM, OWENSBY D, CHESTERMAN CN: A ty-rosinated peptide representing the alternatively spliced exon of the platelet-derived growth factor A-chain binds specifically to cultured cells and interferes with binding of several growth factors. J. Biol. Chem. (1992) 267:1660–1666.
   PubMed Web of Science ®Google Scholar
• VLODAVSKY I, MIAO HQ, ATZMON R et al.: Control ofcell proliferation by heparan sulfate and heparin-binding growth factors. Thromb. Haemost. (1995) 74:534–540.
   PubMed Web of Science ®Google Scholar
• LIN Y, RECKTENWALD A, SILVER P, NGUYEN L: Hepari-nase III inhibits heparin-binding growth factor-mediated proliferation and migration of rat A10 vascu-lar smooth muscle cells. Mol. Biol. Cell (1997) 8:393a. Ab-stract.
   Google Scholar
• NGUYEN L, LIN Y, DENHOLM EM, SILVER P: Modulationof platelet-derived growth factor-BB activity by hepari-nase III (IBT 9302). FASEB J Abstract. (In press.)
   Google Scholar
• LINDNER V, REIDY MA: Proliferation of smooth musclecells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA (1991) 88:3739–3743.
   PubMed Web of Science ®Google Scholar
• FERNS GA, RAINES EW, SPRUGEL KH et al: Inhibition ofneointimal smooth muscle accumulation after angio-plasty by an antibody to PDGF. Science (1991) 253:1129–1132.
   PubMed Web of Science ®Google Scholar
• PIERCE G, MUSTOE TA: Pharmacologic enhancement of wound healing. Ann. Rev. Med. (1995) 46:467-481. Paul J Silver
   Google Scholar